Cazares v. Ortho El Paso, P.A.

CourtDistrict Court, W.D. Texas
DecidedJune 12, 2020
Docket3:20-cv-00005
StatusUnknown

This text of Cazares v. Ortho El Paso, P.A. (Cazares v. Ortho El Paso, P.A.) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cazares v. Ortho El Paso, P.A., (W.D. Tex. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS EL PASO DIVISION

JAVIER CADENA CAZARES and § ANGELINA CAZARES, § Plaintiffs, § § v. § NO. EP-20-CV-05-PRM § ORTHO EL PASO, P.A., et al., § Defendants. §

REPORT AND RECOMMENDATION OF MAGISTRATE JUDGE

Before the Court are “Plaintiffs’ Motion to Remand” (“Motion to Remand”) (ECF No. 4), filed by Plaintiffs Javier Cadena Cazares and Angelina Cazares, and “Defendant Ortho El Paso, P.A.’s Motion to Dismiss for Failure to State a Claim Upon Which Relief May Be Granted” (“Motion to Dismiss”) (ECF No. 10), filed by Defendant Ortho El Paso, P.A. (“Ortho El Paso”).1 The District Court referred these motions to this Court for Report and Recommendation pursuant to 28 U.S.C. § 636(b)(1)(B) and Rule 1(d) of Appendix C to the Local Rules of the United States District Court for the Western District of Texas. (ECF No. 20). For the following reasons, the Court RECOMMENDS that the Motion to Remand be GRANTED and the case be REMANDED. I. BACKGROUND In this lawsuit, Plaintiffs allege that Plaintiff Javier Cazares received an injection of “the drug Synvisc-One® (Hylan g-f20)” (“Synvisc-One”) for his knee pain and that the Synvisc-One syringe was contaminated, causing Plaintiffs to sustain injuries. (Plaintiffs’ First Amended

1 Both motions are based on many of the same factual and legal arguments. Accordingly, the Court finds it efficient to address both motions in a single Report and Recommendation. Petition, ECF No. 1-1, at 8–9) (hereinafter “Pet.”). Plaintiffs bring claims against several named defendants2 of strict liability, manufacturing defect, negligence, breach of express warranty, and breach of the implied warranties of merchantability and fitness for a particular purpose. Id. at 9– 12. The “Factual Background” alleged in Plaintiffs’ First Amended Petition is as follows: The named Defendants are manufacturers, designers, producers, marketers, sellers, handlers, and/or distributors of the drug Synvisc-One® (Hylan g-f20). Following a surge in complaints related to a contaminated batch of Synvisc-One® syringes, the Defendants initiated a voluntary recall of the 12,380 syringes in single lot number 7RSL021 (“Contaminated Lot”). The Defendants’ recall notice cited a lack of environmental control which resulted in microbial contamination to the syringes in the recalled lot. The Contaminated Lot was produced at the Defendants’ plant in Ridgefield, New Jersey and distributed between October 25, 2017 and November 7, 2017.

On November 9, 2017, Mr. Cazares was suffering from osteoarthritis in his knee. Plaintiff’s doctor, working from Defendant Ortho El Paso’s facility where the drug was ultimately distributed and sold for final use, administered a dose of contaminated Synvisc-One® to Mr. Cazares for his knee pain. The contaminated syringe was placed into the stream of commerce by all named Defendants, who at all times relevant to this lawsuit, maintained exclusive control of the manufacture, distribution, sale, and administration of the bacteria-infused Synvisc-One®. Due to the bacterial cocktail he was injected with, Mr. Cazares suffered an immediate adverse reaction and subsequent infection that eventually necessitated several surgeries, months of therapy, and numerous hospitalizations. As a result of the injuries caused by the Defendants, both Plaintiffs sustained severe injuries described below.

Id. at 8–9. Plaintiffs initially filed suit in the 34th Judicial District Court in El Paso County, Texas, on November 8, 2019, and filed their First Amended Petition in that court on January 2, 2020. Id. at 2–4. On January 8, 2020, the case was removed to the United States District Court for the Western

2 Plaintiffs also name “Defendant, John Doe Corporation.” (Pet., ECF No. 1-1, at 8). However, “the citizenship of defendants sued under fictitious names shall be disregarded” when determining whether removal is proper on the basis of diversity jurisdiction. 28 U.S.C. § 1441(b)(1). District of Texas, El Paso Division by Defendants Aventis Inc.; Aventis Pharmaceutical, Inc.; Aventis Pharmaceuticals, Inc.; Sanofi SA; Sanofi U.S.; Sanofi-Aventis; Sanofi-Aventis LLC; Sanofi-Aventis U.S. LLC; Sanofi U.S. Services, Inc.; Sanofi Pasteur; Sanofi Genzyme; Genzyme Corporation; and Genzyme Biosurgery (hereinafter “Removing Defendants”). (Notice of Removal, ECF No. 1, at 1) (hereinafter (“Rem. Not.”). Removing Defendants attached to their

Notice of Removal the “Notice of Consent to Removal” of Defendant CVS Pharmacy, Inc. (“incorrectly sued here as CVS Health, Inc. and CVS Caremark, Inc.”), (ECF No. 1-4, at 2–3), and Defendant Capital Returns, Inc. d/b/a Genco Pharmaceutical Services, id. at 4–5, (both Defendants hereinafter included in “Removing Defendants”).3 In the Notice of Removal, Removing Defendants assert that removal is proper on the basis of original diversity jurisdiction, contending that the amount in controversy requirement is met and there is complete diversity of the parties properly joined. (Rem. Not., ECF No. 1, at 2). Removing Defendants further argue that the presence of Ortho El Paso, which did not join in removal, does not defeat diversity of the parties because Ortho El Paso was improperly joined to this lawsuit. Id. at 3.

On February 7, 2020, Plaintiffs filed the instant Motion to Remand arguing that this Court did not have subject matter jurisdiction because the parties are not diverse, specifically because Ortho El Paso is a proper party to this lawsuit. (Motion to Remand, ECF No. 4) (hereinafter (“Remand Mot.”). Removing Defendants filed a response in opposition on February 13, 2020. (Defendants’ Response in Opposition to Plaintiffs’ Motion to Remand, ECF No. 7) (hereinafter “Remand Mot. Opp.”). On February 25, 2020, Ortho El Paso filed the instant Motion to Dismiss, raising essentially the same arguments as those found in the Notice of Removal and Removing Defendants’ Response in Opposition to Plaintiffs’ Motion to Remand. (ECF No. 10). On March

3 Each Notice of Consent to Removal stated that the respective Defendant “fully joins in with the Notice of Removal.” (ECF No. 1-4, at 2, 4). 10, 2020, Plaintiffs’ filed a response in opposition to the Motion to Dismiss, arguing that the Motion to Dismiss is untimely. (ECF No. 12). Ortho El Paso filed a reply thereto on March 13, 2020. (ECF No. 13). II. LEGAL STANDARD A. MOTION TO REMAND

i. Removal Based on Diversity Jurisdiction In general, pursuant to 28 U.S.C. § 1441(a), the defendant(s) to a civil action brought in state court may remove the action to the proper United States district court where such district court has original jurisdiction of the action. “A federal district court may exercise original jurisdiction over any civil action that either satisfies diversity requirements or that arises under the federal constitution, statutes, or treaties—commonly referred to as ‘federal question’ jurisdiction.” Energy Mgmt. Servs., LLC v. City of Alexandria, 739 F.3d 255, 258–59 (5th Cir. 2014) (citing 28 U.S.C. §§ 1331, 1332, 1369). For diversity jurisdiction, federal district courts “have original jurisdiction of all civil actions where the matter in controversy exceeds the sum or value of $75,000 . . . and is between . . . citizens of different states . . . .” 28 U.S.C. § 1332(a)(1).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Oppenheimer v. Prudential Securities Inc.
94 F.3d 189 (Fifth Circuit, 1996)
Spivey v. Robertson
197 F.3d 772 (Fifth Circuit, 1999)
Acuna v. Brown & Root Inc.
200 F.3d 335 (Fifth Circuit, 2000)
Howe v. Scottsdale Insurance Co.
204 F.3d 624 (Fifth Circuit, 2000)
Howery v. Allstate Ins Company
243 F.3d 912 (Fifth Circuit, 2001)
Manguno v. Prudential Property & Casualty Insurance
276 F.3d 720 (Fifth Circuit, 2002)
Travis v. Irby
326 F.3d 644 (Fifth Circuit, 2003)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Burr Stafford v. Mobil Oil Corporation
945 F.2d 803 (Fifth Circuit, 1991)
Medical City Dallas, Ltd. v. Carlisle Corp.
251 S.W.3d 55 (Texas Supreme Court, 2008)
Hadley v. WYETH LABORATORIES, INC.
287 S.W.3d 847 (Court of Appeals of Texas, 2009)
Easterly v. HSP of Texas, Inc.
772 S.W.2d 211 (Court of Appeals of Texas, 1989)
General Supply and Equipment Co., Inc. v. Phillips
490 S.W.2d 913 (Court of Appeals of Texas, 1972)
Providence Hospital v. Truly
611 S.W.2d 127 (Court of Appeals of Texas, 1980)
Walden v. Jeffery
907 S.W.2d 446 (Texas Supreme Court, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
Cazares v. Ortho El Paso, P.A., Counsel Stack Legal Research, https://law.counselstack.com/opinion/cazares-v-ortho-el-paso-pa-txwd-2020.